Analysis of the BRAFV600E mutation in central nervous system tumors

Translational Oncology

Volumn 5, Issue 6, 2012, Pages 430-436

  Myung, Jae Kyung ^a   Cho, Hwajin ^a   Park, Chul Kee ^a   Kim, Seung Ki ^a,b   Lee, Se Hoon ^a   Park, Sung Hye ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Children's Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER GRADING; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; DNA METHYLATION; DNA PURIFICATION; DNA SEQUENCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PATHOLOGY; PILOCYTIC ASTROCYTOMA; PLEOMORPHIC XANTHOASTROCYTOMA; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 84871704107     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12328     Document Type: Article

References (33)

1. Peyssonnaux C and Eychene A (2001). The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93, 53-62.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
3. Michaloglou C, Vredeveld LC, Mooi WJ, and Peeper DS (2008). BRAFE600 in benign and malignant human tumours. Oncogene 27, 877-895.
4. Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, and Rajan MG (2011). BRAFV600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol 23, 83-93.
5. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, and Reis RM (2005). Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109, 207-210.
6. El-Habr EA, Tsiorva P, Theodorou M, Levidou G, Korkolopoulou P, Vretakos G, Petraki L, Michalopoulos NV, Patsouris E, and Saetta AA (2010). Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT. Clin Neuropathol 29, 239-245.
7. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, and Wesseling P (2007). RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114, 121-133.
8. Knobbe CB, Reifenberger J, and Reifenberger G (2004). Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108, 467-470.
9. Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, Kuhnel S, Meyer C, Rapp UR, Kammerer U, Vordermark D, et al. (2009). RAF expression in human astrocytic tumors. Int J Mol Med 23, 17-31.
10. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, et al. (2011). Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121, 397-405.
11. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, et al. (2011). BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6, e17948.
12. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, and Biegel JA (2010). Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12, 621-630.
13. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, et al. (2009). Activation of the ERK/ MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218, 172-181.
14. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, et al. (2009). Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 101, 722-733.
15. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, et al. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70, 512-519.
16. Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, and Gutmann DH (2009). Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 73, 1526-1531.
17. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, et al. (2011). BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17, 4790-4798.
18. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, et al. (2007). Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26, 1088-1097.
19. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, and Peeper DS (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
20. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90, 1473-1479.
21. Nikiforov YE (2011). Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135, 569-577.
22. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, and von Deimling A (2011). Assessment of BRAF V600E mutation status by immunohistochemistry with a mutationspecific monoclonal antibody. Acta Neuropathol 122, 11-19.
23. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11, 753-762.
24. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26, 5705-5712.
25. Arkenau HT, Kefford R, and Long GV (2011). Targeting BRAF for patients with melanoma. Br J Cancer 104, 392-398.
26. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363, 809-819.
27. Poulikakos PI, Zhang C, Bollag G, Shokat KM, and Rosen N (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
28. Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, et al. (2011). Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17, 7595-7604.
29. James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, et al. (2012). CEP-32496: a novel orally active BRAFV600E inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther 11, 930-941.
30. Jeon YK, Park K, Park CK, Paek SH, Jung HW, and Park SH (2007). Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology 27, 10-20.
31. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, and Kim WH (2008). EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52, 738-746.
32. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A, et al. (2010). Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28, 3182-3190.
33. Myung JK, Byeon SJ, Kim B, Suh J, Kim SK, Park CK, Chung CK, Chang KH, and Park SH (2011). Papillary glioneuronal tumors: a review of clinicopathologic and molecular genetic studies. Am J Surg Pathol 35, 1794-1805.